THE VALUE OF COMPLEMENT ACTIVATION PRODUCTS IN THE ASSESSMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS FLARES

被引:49
|
作者
PORCEL, JM
ORDI, J
CASTROSALOMO, A
VILARDELL, M
RODRIGO, MJ
GENE, T
WARBURTON, F
KRAUS, M
VERGANI, D
机构
[1] HOSP GEN VALLE HEBRON,DEPT INTERNAL MED,BARCELONA,SPAIN
[2] HOSP GEN VALLE HEBRON,DEPT BIOCHEM,BARCELONA,SPAIN
[3] ST THOMAS HOSP,DEPT PUBL HLTH MED,COMP MED UNIT,LONDON,ENGLAND
[4] BEHRINGWERKE AG,RES LABS,W-3550 MARBURG,GERMANY
[5] UNIV LONDON SCH MED,LONDON,ENGLAND
来源
关键词
D O I
10.1006/clin.1995.1040
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complement activation products (CAP) have been reported as sensitive markers of disease activity in systemic lupus erythematosus (SLE). We have measured seven parameters of the complement system (C3, C4, factor B, C3a, C4a, iC3b, and the terminal complement complex -TCC-) in 61 SLE patients to study their interrelationship and relative efficacy as diagnostic indicators of lupus activity. Disease activity was judged according to a clinical index (SLEDAI) to be active in 22 and inactive in 39 patients. Subjects with active SLE showed increased levels of C3a, C4a, and TCC compared with those of stable lupus and normal controls, and plasma concentrations of these CAP manifested a positive correlation with disease activity scores. However, values of factor B and iC3b did not correlate with lupus flares. Serum C3 levels were a better reflection of the degree of SLE activity than were C4 levels. The anaphylatoxins were extremely sensitive markers of disease activity but they lacked enough specificity, and iC3b was not at all informative for this purpose. On the whole, TCC concentration was the most useful parameter (77% sensitivity, 80% specificity) to monitor lupus activity, correlating the best with the activity scoring system, and thus offers a better laboratory marker of lupus severity than conventional measurements of complement. (C) 1995 Academic Press, Inc.
引用
收藏
页码:283 / 288
页数:6
相关论文
共 50 条
  • [1] ACTIVATION OF COMPLEMENT IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    PORCEL, JM
    ORDI, J
    MEDICINA CLINICA, 1991, 96 (04): : 135 - 137
  • [2] COMPLEMENT ACTIVATION AND COMPLEMENT RECEPTORS IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ATKINSON, JP
    SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1986, 9 (2-3): : 179 - 194
  • [3] COMPLEMENT ACTIVATION IN SYSTEMIC LUPUS-ERYTHEMATOSUS (SLE)
    STURFELT, G
    JOHNSON, U
    SJOHOLM, AG
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1984, 20 (02) : 181 - 181
  • [4] ACTIVATION OF THE ALTERNATIVE COMPLEMENT PATHWAY ACCOMPANIES DISEASE FLARES IN SYSTEMIC LUPUS-ERYTHEMATOSUS DURING PREGNANCY
    BUYON, JP
    TAMERIUS, J
    ORDORICA, S
    YOUNG, B
    ABRAMSON, SB
    ARTHRITIS AND RHEUMATISM, 1992, 35 (01): : 55 - 61
  • [5] COMPLEMENT ACTIVATION AND VASCULAR INJURY IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ABRAMSON, S
    BELMONT, HM
    HOPKINS, P
    BUYON, J
    WINCHESTER, R
    WEISSMANN, G
    JOURNAL OF RHEUMATOLOGY, 1987, 14 : 43 - 46
  • [6] ACTIVATION OF ALTERNATIVE COMPLEMENT PATHWAY IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    WILSON, MR
    ARROYAVE, CM
    NAKAMURA, RM
    VAUGHAN, JH
    TAN, EM
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1976, 26 (01): : 11 - 20
  • [7] SEQUENTIAL STUDIES OF COMPLEMENT ACTIVATION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    STURFELT, G
    JOHNSON, U
    SJOHOLM, AG
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1985, 14 (02) : 184 - 196
  • [8] COMPLEMENT ACTIVATION BY ANTIBODIES TO SM IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    SABHARWAL, UK
    FONG, S
    HOCH, S
    COOK, RD
    VAUGHAN, JH
    CURD, JG
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1983, 51 (02): : 317 - 324
  • [9] COMPLEMENT ACTIVATION BY ANTIBODIES TO SM IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    SABHARWAL, UK
    FONG, S
    HOCH, SO
    COOK, RD
    KOHLER, PF
    VAUGHAN, JH
    CURD, JG
    CLINICAL RESEARCH, 1982, 30 (01): : A55 - A55
  • [10] COMPLEMENT ACTIVATION IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A MARKER OF INFLAMMATION
    KERR, LD
    ADELSBERG, BR
    SPIERA, H
    JOURNAL OF RHEUMATOLOGY, 1986, 13 (02) : 313 - 319